Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer

Next Previous
X
Search
Trial Profile

Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talazoparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Advanced breast cancer; Cholangiocarcinoma; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Jan 2020 Status changed from active, no longer recruiting to discontinued.
    • 15 Jun 2018 Planned primary completion date changed from 1 May 2016 to 1 Jan 2019.
    • 25 Oct 2017 Outcomes of pharmacokinetic-toxicity model developed using data from this trial, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top